Relay Therapeutics, Inc. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
Relay Therapeutics, Inc. (RLAY) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of -$2.69 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2022-08-04
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2022-06-30 was -$2.69M.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2022-03-31 was -$8.13M.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2021-06-30 was -$76.00K.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2021-03-31 was -$52.00K.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2021 was -$1.15M.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2020 was -$261.00K, a 180.31% decline from fiscal 2019.
- Relay Therapeutics, Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2019 was $325.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|
| 2022-06-30 | -$2.69M 10-Q · filed 2022-08-04 | -$10.82M derived: sum of 2 quarters · filed 2022-08-04 | |
| 2022-03-31 | -$8.13M 10-Q · filed 2022-08-04 | ||
| 2021-12-31 | -$1.15M 10-K · filed 2022-02-24 | ||
| 2021-06-30 | -$76.00K 10-Q · filed 2022-08-04 | -$128.00K derived: sum of 2 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$52.00K 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | -$261.00K 10-K · filed 2022-02-24 | ||
| 2019-12-31 | $325.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |